Venous thromboembolism prophylaxis in hospitalized sickle cell disease and sickle cell trait patients.

Filip IonescuNwabundo AnusimMarkie S ZimmerIshmael Jaiyesimi

Published in: European journal of haematology (2022)

VTEP is underused in Hb SS/Hb SA patients. There may be a trend toward offering more VTEP in Hb SS disease, but not in Hb SA patients, where VTEP prescribing is driven by comorbid conditions rather than genotype. Patient compliance does not appear to play a major role, but intercenter variability suggests provider education may improve VTEP use.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
venous thromboembolism
chronic kidney disease
primary care
sickle cell disease
peritoneal dialysis
emergency department
gene expression
genome wide
atrial fibrillation
quality improvement
direct oral anticoagulants